Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Leuk Res

Retrieve available abstracts of 138 articles:
HTML format

Single Articles

    November 2021
  1. MIRFAKHRAIE R, Noorazar L, Mohammadian M, Hajifathali A, et al
    Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.
    Leuk Res. 2021;112:106751.
    PubMed     Abstract available

  2. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
    Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
    Leuk Res. 2021;111:106747.

    October 2021
  3. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
    Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Leuk Res. 2021;111:106736.
    PubMed     Abstract available

  4. CHOW S, Tang K, Al-Abri M, Hall V, et al
    RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2021;111:106735.

  5. KANNAN KK, Vellanki P, Isom S, Tawfik B, et al
    Re-induction therapy in adult patients with acute myeloid leukemia with
    Leuk Res. 2021;111:106731.

  6. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
    Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
    Leuk Res. 2021;111:106729.
    PubMed     Abstract available

  7. PADMAKUMAR D, Chandraprabha VR, Gopinath P, Vimala Devi ART, et al
    A concise review on the molecular genetics of acute myeloid leukemia.
    Leuk Res. 2021;111:106727.
    PubMed     Abstract available

  8. PARK H, Kim I, Kim HJ, Shin DY, et al
    Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
    Leuk Res. 2021;111:106728.
    PubMed     Abstract available

  9. MARTINEZ-VERBO L, Estrada N, Cabezon M, Palomo L, et al
    Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
    Leuk Res. 2021;111:106726.

    September 2021
  10. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
    Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
    Leuk Res. 2021;110:106702.
    PubMed     Abstract available

  11. ESFANDBOD M, Enshaei M, Monzavi SM, Kabootari M, et al
    Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
    Leuk Res. 2021;111:106703.
    PubMed     Abstract available

  12. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
    Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
    Leuk Res. 2021;110:106707.
    PubMed     Abstract available

  13. DU X, Liu H, Yang C, Shi X, et al
    LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106706.
    PubMed     Abstract available

  14. ALVAREZ N, Rodriguez-Garcia A, Morales ML, Gutierrez M, et al
    Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
    Leuk Res. 2021;108:106613.

  15. ALEISSA MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, et al
    Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
    Leuk Res. 2021;108:106610.
    PubMed     Abstract available

  16. LINCH DC, Hills RK, Gilkes A, Burnett AK, et al
    Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
    Leuk Res. 2021;108:106553.
    PubMed     Abstract available

    August 2021
  17. YU J, Du Y, Jalil A, Ahmed Z, et al
    Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
    Leuk Res. 2021;110:106701.
    PubMed     Abstract available

  18. ABRAMENKO I, Bilous N, Chumak A, Kryachok I, et al
    The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Leuk Res. 2021;110:106686.
    PubMed     Abstract available

  19. DARASKEVICIUS J, Everatt V, Vaitekenaite V, Ringeleviciute U, et al
    Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
    Leuk Res. 2021;111:106692.

  20. RAHIMI Z, Ghorbani Z, Motamed H, Jalilian N, et al
    Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
    Leuk Res. 2021;111:106691.
    PubMed     Abstract available

  21. YOUNG PE, Kanagal-Shamanna R, Hu S, Tang G, et al
    Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
    Leuk Res. 2021;111:106685.

  22. GOWIN K, Skerget S, Keats JJ, Mikhael J, et al
    Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
    Leuk Res. 2021;111:106687.
    PubMed     Abstract available

  23. GUPTA SK, Bakhshi S, Kamal VK, Gupta R, et al
    Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Leuk Res. 2021;111:106683.
    PubMed     Abstract available

    July 2021
  24. PLESA A, Roumier C, Gutrin J, Larcher MV, et al
    Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
    Leuk Res. 2021;111:106673.

  25. MA CE, Ghosh S, Leyshon C, Blosser N, et al
    Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
    Leuk Res. 2021;111:106674.
    PubMed     Abstract available

  26. ALSHEMMARI SH, Hamdah A, Pandita R, Kunhikrishnan A, et al
    Chronic lymphocytic leukemia in a young population.
    Leuk Res. 2021;110:106668.
    PubMed     Abstract available

  27. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
    Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
    Leuk Res. 2021;110:106666.
    PubMed     Abstract available

  28. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
    Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106665.
    PubMed     Abstract available

  29. SMITH MR, Cronin JF, Weiss RF
    Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
    Leuk Res. 2021;110:106663.
    PubMed     Abstract available

  30. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
    The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
    Leuk Res. 2021;110:106662.

  31. IBRAHIM M, Chen R, Vegel A, Panse K, et al
    Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen.
    Leuk Res. 2021;106:106583.

  32. GLASS JL, Derkach A, Hilden P, King A, et al
    Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
    Leuk Res. 2021;106:106569.
    PubMed     Abstract available

    June 2021
  33. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
    Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Leuk Res. 2021;109:106650.

  34. CHENG L, Zeng S, Yan D, Tu L, et al
    Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
    Leuk Res. 2021;109:106649.
    PubMed     Abstract available

  35. ZHANG Y, Feng S
    The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106647.
    PubMed     Abstract available

  36. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
    miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106643.
    PubMed     Abstract available

  37. GUPTA SK, Singh P, Chhabra R, Verma M, et al
    Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Leuk Res. 2021;109:106641.
    PubMed     Abstract available

  38. HUNTER AM, Al Ali N, Mai A, Shah S, et al
    Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
    Leuk Res. 2021;109:106640.

  39. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
    Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
    Leuk Res. 2021;109:106612.
    PubMed     Abstract available

  40. SONG J, Shang B, Pei Y, Shi M, et al
    A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Leuk Res. 2021;109:106638.
    PubMed     Abstract available

  41. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
    Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leuk Res. 2021;109:106628.
    PubMed     Abstract available

    Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
    Leuk Res. 2021;105:106572.

  43. MIYAUCHI J, Kawaguchi H
    The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
    Leuk Res. 2021;105:106570.
    PubMed     Abstract available

    May 2021
  44. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Leuk Res. 2021;108:106627.
    PubMed     Abstract available

  45. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
    Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
    Leuk Res. 2021;108:106616.
    PubMed     Abstract available

  46. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
    Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
    Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.

  47. ALI H, Salhotra A, Stein AS, Nakamura R, et al
    Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
    Leuk Res. 2021;104:106579.

  48. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
    Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
    Leuk Res. 2021;104:106541.

    April 2021
  49. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
    Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
    Leuk Res. 2021;107:106603.
    PubMed     Abstract available

  50. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res. 2021;107:106604.
    PubMed     Abstract available

  51. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
    WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
    Leuk Res. 2021;108:106587.

  52. VACHHANI P, Baron J, Freyer CW, Miller A, et al
    A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Leuk Res. 2021;107:106588.
    PubMed     Abstract available

  53. CHEN P, Redd L, Schmidt Y, Koduru P, et al
    MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
    Leuk Res. 2021;106:106584.
    PubMed     Abstract available

  54. PETRICK L, Imani P, Perttula K, Yano Y, et al
    Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
    Leuk Res. 2021;106:106585.
    PubMed     Abstract available

  55. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
    Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
    Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.

  56. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
    Leuk Res. 2021;106:106567.

  57. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
    Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Leuk Res. 2021;103:106540.
    PubMed     Abstract available

    March 2021
  58. PARK S, Choi EJ, Lee H, Jo DY, et al
    Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
    Leuk Res. 2021;105:106578.
    PubMed     Abstract available

  59. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
    A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Leuk Res. 2021;105:106573.
    PubMed     Abstract available

  60. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
    Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
    Leuk Res. 2021;104:106571.

  61. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
    Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Leuk Res. 2021;105:106568.
    PubMed     Abstract available

  62. NI J, Hong J, Li Q, Zeng Q, et al
    Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
    Leuk Res. 2021;105:106564.
    PubMed     Abstract available

  63. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480].
    Leuk Res. 2021 Mar 26:106563. doi: 10.1016/j.leukres.2021.106563.

  64. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
    Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
    Leuk Res. 2021;102:106523.
    PubMed     Abstract available

    February 2021
  65. REID JH, Perissinotti AJ, Benitez LL, Boyer D, et al
    Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
    Leuk Res. 2021;103:106539.
    PubMed     Abstract available

  66. HUANG SJ, Gerrie AS, Young S, Tucker T, et al
    Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
    Leuk Res. 2021;103:106538.
    PubMed     Abstract available

  67. SHIMIZU H, Yokohama A, Ishizaki T, Hatsumi N, et al
    Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2021;103:106535.
    PubMed     Abstract available

  68. PAROVICHNIKOVA EN, Troitskaya VV, Gavrilina OA, Sokolov AN, et al
    The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009.
    Leuk Res. 2021;104:106536.
    PubMed     Abstract available

  69. JEURKAR C, Wilde L, Leiby BE, Banks J, et al
    Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
    Leuk Res. 2021;103:106533.
    PubMed     Abstract available

  70. BOULIGNY IM, Mehta V, Isom S, Ellis LR, et al
    Efficacy of 10-day decitabine in acute myeloid leukemia.
    Leuk Res. 2021;103:106524.
    PubMed     Abstract available

  71. SOLMAN IG, Blum LK, Burger JA, Kipps TJ, et al
    Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Leuk Res. 2021;102:106520.
    PubMed     Abstract available

  72. MOORE JE, Delibert K, Baran AM, Evans AG, et al
    Targeted therapy for treatment of patients with classical hairy cell leukemia.
    Leuk Res. 2021;102:106522.
    PubMed     Abstract available

  73. SEGURO FS, Maciel FVR, Santos FM, Abdo ANR, et al
    MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
    Leuk Res. 2021;101:106516.
    PubMed     Abstract available

    January 2021
  74. MARTIN-MORO F, Nunez-Torron C, Perez-Lamas L, Jimenez-Chillon C, et al
    The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid.
    Leuk Res. 2021;101:106518.

  75. OCHS MA, Perissinotti AJ, Marini BL, Burke PW, et al
    Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Leuk Res. 2021;102:106517.
    PubMed     Abstract available

  76. GHALESARDI OK, Khosravi A, Azizi E, Ahmadi SE, et al
    The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
    Leuk Res. 2021;101:106512.
    PubMed     Abstract available

  77. MONTALBAN-BRAVO G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, et al
    Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.
    Leuk Res. 2021;101:106511.
    PubMed     Abstract available

  78. ZENT CS, Ross DM
    Changing of the guard: Leukemia Research 2021.
    Leuk Res. 2021 Jan 13:106510. doi: 10.1016/j.leukres.2021.106510.

  79. ACHA P, Hoyos M, Pratcorona M, Fuster-Tormo F, et al
    Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
    Leuk Res. 2021;101:106492.

  80. PELCOVITS A, Pandita A, Farmakiotis D, Egan P, et al
    Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR.
    Leuk Res. 2021;100:106473.

    December 2020
  81. MARCONI G, De Polo S, Martinelli G, Nanni J, et al
    Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
    Leuk Res. 2020;101:106497.
    PubMed     Abstract available

  82. ADRIANZEN-HERRERA D, Jordan-Bruno X, Devitt KA, Conant JL, et al
    Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.
    Leuk Res. 2020;100:106494.

  83. YASUDA H, Morishita S, Mori Y, Tsukune Y, et al
    JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
    Leuk Res. 2020;100:106496.

  84. DJAMAI H, Berrou J, Dupont M, Kaci A, et al
    Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Leuk Res. 2020;100:106490.
    PubMed     Abstract available

  85. DEMINA I, Voropayev A, Semchenkova A, Zerkalenkova E, et al
    Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2020;100:106491.
    PubMed     Abstract available

  86. YEE K, Papayannidis C, Vey N, Dickinson MJ, et al
    Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study small star, filled.
    Leuk Res. 2020;100:106489.
    PubMed     Abstract available

  87. SHAO H, Wang W, Song J, Tang G, et al
    Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Leuk Res. 2020;99:106460.
    PubMed     Abstract available

  88. KIRKIZLAR TA, Akalin H, Kirkizlar O, Ozkalemkas F, et al
    Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.
    Leuk Res. 2020;99:106463.
    PubMed     Abstract available

  89. MALLER B, Bigness A, Moino D, Greene J, et al
    Sweet's syndrome associated with hematological malignancies.
    Leuk Res. 2020;99:106461.
    PubMed     Abstract available

    November 2020
  90. BENEDETTI E, Barate C, Bruno B, Bramanti E, et al
    Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
    Leuk Res. 2020;100:106488.

  91. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
    Leuk Res. 2020;100:106480.
    PubMed     Abstract available

  92. YANAGISAWA B, Perkins B, Karantanos T, Levis M, et al
    Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Leuk Res. 2020;99:106477.
    PubMed     Abstract available

  93. OBAMA K, Tabuchi T, Inoue H
    Prognostic impact of red cell distribution width in adult T-cell leukemia/lymphoma.
    Leuk Res. 2020;99:106474.

    October 2020
  94. KAUFFMAN MR, Nazemidashtarjandi S, Ghazanfari D, Allen AE, et al
    Evidence that knock down of GSK-3beta in Chronic Myelogenous Leukemia cells augments IFN-gamma-induced apoptosis.
    Leuk Res. 2020;99:106464.
    PubMed     Abstract available

  95. DE BELLIS E, Ottone T, Mercante L, Falconi G, et al
    Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia.
    Leuk Res. 2020;99:106462.
    PubMed     Abstract available

    September 2020
  96. MANLEY PW, Barys L, Cowan-Jacob SW
    The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Leuk Res. 2020;98:106458.
    PubMed     Abstract available

  97. WEI L, Cong J, Yang L, Ye J, et al
    Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].
    Leuk Res. 2020 Sep 24:106446. doi: 10.1016/j.leukres.2020.106446.

  98. TREMBLAY D, Feld J, Dougherty M, Czaplinska T, et al
    Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Leuk Res. 2020;98:106456.

  99. MENGHRAJANI K, Zhang Y, Famulare C, Devlin SM, et al
    Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.
    Leuk Res. 2020;98:106453.
    PubMed     Abstract available

  100. CHERNG HJ, Jain N, Thakral B, Muzzafar T, et al
    Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.
    Leuk Res. 2020;98:106445.

  101. BOYD K, Parcell B, Tauro S
    Immunosuppression in hematological cancer patients with Covid-19 -Uncomplicated infections but delayed viral clearance?
    Leuk Res. 2020;96:106407.

  102. BROWN AL, Hiwase DK
    What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening.
    Leuk Res. 2020;96:106431.

  103. NAGAHARU K, Izumi T, Ueda M, Usui E, et al
    High expression of c-Myc in chronic lymphocytic leukaemia with t(8;14)(q24.1;q32): A case report.
    Leuk Res. 2020;96:106424.

    August 2020
  104. MAGANTI H, Visram A, Shorr R, Fulcher J, et al
    Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.
    Leuk Res. 2020;97:106442.
    PubMed     Abstract available

  105. CICCARELLI BT, Hu T, Wang Q, Kim JJ, et al
    Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Leuk Res. 2020;97:106440.
    PubMed     Abstract available

  106. SOLMAN IG, Blum LK, Hoh HY, Kipps TJ, et al
    Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2020;97:106432.
    PubMed     Abstract available

  107. DEEREN D
    FLAG-Ida is back in.
    Leuk Res. 2020;95:106400.

  108. MOLICA S, Baumann TS, Lentini M, Levato L, et al
    The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
    Leuk Res. 2020;95:106401.

    July 2020
  109. CHANAS-LARUE A, Villalpando-Rodriguez GE, Henson ES, Johnston JB, et al
    Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Leuk Res. 2020;96:106423.
    PubMed     Abstract available

  110. TRAN AA, Miljkovic M, Prasad V
    Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
    Leuk Res. 2020;96:106420.
    PubMed     Abstract available

  111. SABNIS HS, Minson KA, Monroe C, Allen K, et al
    A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Leuk Res. 2020;96:106421.
    PubMed     Abstract available

  112. D'ANGELO CR, Hall A, Woo KM, Kim K, et al
    Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    Leuk Res. 2020;96:106419.
    PubMed     Abstract available

  113. WANG Y, Luo H, Wei M, Becker M, et al
    IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia.
    Leuk Res. 2020;96:106409.
    PubMed     Abstract available

  114. CASELLAS ROMAN HL, Venugopal K, Feng Y, Shabashvili DE, et al
    DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
    Leuk Res. 2020;94:106372.

  115. GEORGE G, Rezazadeh A, Zook F, Pearl N, et al
    Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
    Leuk Res. 2020;94:106368.

    June 2020
  116. KALLEN ME, Koka R, Singh Z, Sanchez-Petitto G, et al
    Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
    Leuk Res. 2020;96:106406.

  117. BRITT A, Mohyuddin GR, McClune B, Singh A, et al
    Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Leuk Res. 2020;95:106402.
    PubMed     Abstract available

  118. ZHENG FY, Lu AD, Zuo YX, Jia YP, et al
    Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
    Leuk Res. 2020;95:106405.
    PubMed     Abstract available

  119. GOLDBERG AD, Atallah E, Rizzieri D, Walter RB, et al
    Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
    Leuk Res. 2020;95:106385.
    PubMed     Abstract available

    May 2020
  120. O'CONNOR-BYRNE N, Quinn J, Glavey SV, Lavin M, et al
    Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy.
    Leuk Res. 2020;95:106390.

  121. SOTO-MERCADO V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, et al
    Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism.
    Leuk Res. 2020;95:106389.
    PubMed     Abstract available

  122. AGUILERA-DIAZ A, Larrayoz MJ, Palomino-Echeverria S, Vazquez I, et al
    Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.
    Leuk Res. 2020;95:106386.
    PubMed     Abstract available

  123. SAITO T, Itoh M, Tohda S
    Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
    Leuk Res. 2020;94:106383.
    PubMed     Abstract available

  124. WANG X, Resendes NM, Shanahan L, Hutchinson L, et al
    Chronic neutrophilic leukemia, a rare case of leukocytosis.
    Leuk Res. 2020;94:106384.

  125. NAVADA SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, et al
    Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Leuk Res. 2020;94:106369.
    PubMed     Abstract available

  126. NAYMAGON L, Mascarenhas J
    Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
    Leuk Res. 2020;94:106356.
    PubMed     Abstract available

  127. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    Corrigendum to "STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype" [Leuk. Res. 78 (2019) 21-23].
    Leuk Res. 2020 May 4:106148. doi: 10.1016/j.leukres.2019.

  128. TALATI C, Goldberg AD, Przespolewski A, Chan O, et al
    Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
    Leuk Res. 2020;93:106367.
    PubMed     Abstract available

    April 2020
  129. PANEESHA S, Pratt G, Parry H, Moss P, et al
    Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.
    Leuk Res. 2020;93:106366.

  130. FRANCH-SARTO M, Anglada Escalona JR, Tuset Beltran V, Ribera Santasusana JM, et al
    A unique case of relapse of plasma cell leukemia in the vitreous humor.
    Leuk Res. 2020;93:106357.

  131. OLIVA EN, Tripepi GL
    Letter to the Editor on the original article "A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia" by Bryant Al, et al. 2018.
    Leuk Res. 2020;93:106355.

  132. DRUHAN LJ, Lance A, Hamilton A, Steuerwald NM, et al
    Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia.
    Leuk Res. 2020;92:106349.

    The highs and lows of venetoclax with hypomethylating agents for refractory AML.
    Leuk Res. 2020;91:106320.

    March 2020
  134. GAVILLET M, Carr Klappert J, Spertini O, Blum S, et al
    Acute leukemia in the time of COVID-19.
    Leuk Res. 2020;92:106353.

  135. YANG W, Xie J, Hou R, Chen X, et al
    Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression.
    Leuk Res. 2020;92:106351.
    PubMed     Abstract available

  136. SODERLUND S, Persson I, Ilander M, Guilhot J, et al
    Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
    Leuk Res. 2020;90:106310.
    PubMed     Abstract available

    November 2019
  137. MASSE A, Roulin L, Pasanisi J, Penneroux J, et al
    BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
    Leuk Res. 2019;87:106269.
    PubMed     Abstract available

    June 2019
  138. KINSELLA FAM, Inman CF, Gudger A, Chan YT, et al
    Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
    Leuk Res. 2019;83:106173.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.